Nine Masts Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Nine Masts Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$150K	Buy	+286	New	+$146K	0.02%	185

Other funds holding VRTX

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Nine Masts Capital's VRTX Position: Q3 2026 in Review

Nine Masts Capital opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 286 shares worth $150K. The stake represents 0.02% of the portfolio and ranks #185 among its holdings.

1,356 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Nine Masts Capital held 286 shares of Vertex Pharmaceuticals worth $150K as of Q3 2026.
Vertex Pharmaceuticals was a new Nine Masts Capital position in Q3 2026.
Vertex Pharmaceuticals made up 0.02% of Nine Masts Capital's portfolio in Q3 2026, its #185 holding.
1,356 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Nine Masts Capital's 13F filing for Q3 2026, filed 9 Nov 2026.